(Q39327918)

11 September 2017

title

Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer (English)

1 reference

11 September 2017

main subject

human papillomavirus 16

1 reference

1 reference

cervix uterine cancer

1 reference

Chandresh Sharma

1

1 reference

11 September 2017

Bindu Dey

series ordinal

2

1 reference

11 September 2017

Mohammed Wahiduzzaman

series ordinal

3

1 reference

11 September 2017

Neeta Singh

series ordinal

4

1 reference

11 September 2017

language of work or name

English

0 references

publication date

17 June 2012

1 reference

11 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

11 September 2017

volume

30

1 reference

11 September 2017

issue

36

1 reference

11 September 2017

page(s)

5417-5424

1 reference

The viral etiology of cervical cancer

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Papillomaviruses and cancer: from basic studies to clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

L1-specific protection from tumor challenge elicited by HPV16 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Human papillomavirus in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Introducing HPV vaccine in developing countries--key challenges and issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Chimeric papillomavirus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

A deletion and point mutation study of the human papillomavirus type 16 major capsid gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Molecular variants of HPV-16 associated with cervical cancer in Indian population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Impaired Antigen Presentation and Effectiveness of Combined Active/Passive Immunotherapy for Epithelial Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.010

10.1016/J.VACCINE.2012.06.010

7 January 2021

Identifiers

DOI

1 reference

11 September 2017

1 reference